TY - JOUR
T1 - Sarcopenia, Aging and Prospective Interventional Strategies
AU - Waltz, Tyler B
AU - Fivenson, Elayne M
AU - Morevati, Marya
AU - Li, Chuanhao
AU - Becker, Kevin G
AU - Bohr, Vilhelm A
AU - Fang, Evandro F
N1 - Copyright© Bentham Science Publishers; For any queries, please email at [email protected].
PY - 2018
Y1 - 2018
N2 - Sarcopenia, or age-related muscle decline, occurs in most organisms and burdens both human health and the healthcare system. As our population ages, additional options for treating sarcopenia are needed. Mitochondrial dysfunction is implicated in the onset of sarcopenia, so therapies directed at improving mitochondrial function in muscle should be considered. Many naturally-occurring compounds, derived from commonly consumed foods, possess anti-sarcopenic effects, such asnicotinamide riboside, tomatidine, and Urolithin A. These naturally-occurring compounds can improve mitochondrial health and efficiency by modulating mitochondrial biogenesis, cellular stress resistance, or mitophagy. Further research should assess whether compounds that improve mitochondrial health can attenuate sarcopenia in humans.
AB - Sarcopenia, or age-related muscle decline, occurs in most organisms and burdens both human health and the healthcare system. As our population ages, additional options for treating sarcopenia are needed. Mitochondrial dysfunction is implicated in the onset of sarcopenia, so therapies directed at improving mitochondrial function in muscle should be considered. Many naturally-occurring compounds, derived from commonly consumed foods, possess anti-sarcopenic effects, such asnicotinamide riboside, tomatidine, and Urolithin A. These naturally-occurring compounds can improve mitochondrial health and efficiency by modulating mitochondrial biogenesis, cellular stress resistance, or mitophagy. Further research should assess whether compounds that improve mitochondrial health can attenuate sarcopenia in humans.
U2 - 10.2174/0929867324666170801095850
DO - 10.2174/0929867324666170801095850
M3 - Review
C2 - 28762310
VL - 25
SP - 5588
EP - 5596
JO - Current Medicinal Chemistry
JF - Current Medicinal Chemistry
SN - 0929-8673
IS - 40
ER -